Vertex Pharmaceuticals Incorporated - Common Stock (VRTX)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — Aug 5, 2026Investment Snapshot
- Trading 157% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 5/9 — moderate financial health
- Strong ROE of 21.0% with 34.4% net margin
- Revenue growing at 9% annually
Vertex Pharmaceuticals Incorporated - Common Stock (VRTX) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $113.3 billion . Key value metrics: P/E ratio 26.7, P/B ratio 5.59, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Vertex Pharmaceuticals Incorporated - Common Stock — Fundamental Analysis Summary
Vertex Pharmaceuticals Incorporated - Common Stock (VRTX) is currently trading 157% above its Graham Number of $173.54, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 26.7x.
On financial health, VRTX shows a moderate Piotroski F-Score of 5/9, and strong return on equity of 21.0% (sector average: -20.1%), and manageable leverage with a debt-to-equity ratio of 0.37.
StockPik's composite Value Score for VRTX is 74/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
VRTX reports a high gross margin of 86.2% (sector average: 37.4%) and a strong operating margin of 38.2%.
VRTX shows revenue growing at 9% year-over-year, with earnings growing at 838%.